Research Library
Peptide research, regulatory updates, and protocol intelligence.
Grounded in peer-reviewed literature and FDA prescribing data — the same sources that power the PeptidesGPT AI Coach.
Bloomberg Just Put Peptides on the Cover. Here's What It Got Right — And What the Story Missed.
Bloomberg Businessweek's peptide cover story describes a multibillion-dollar gold rush. Here's the context the article didn't have space to explain — and what it means for anyone navigating this space.
Why I Stopped Chasing My Goal Weight — And What I Track Instead
I hit my goal weight of 168 lbs — and my body composition data told a different story: muscle down, body fat up. Here's why I track SMM and body-fat %, not just the scale.
What Lilly's Top Obesity Executive Just Said About the Future of Metabolic Medicine
At the Goldman Sachs 47th Annual Healthcare Conference, Lilly's EVP of Cardiometabolic Health framed GIP, GLP-1, and amylin as the three hormones that belong together. Here's what that signals.
You're on a GLP-1. Here's Why You Need a System Before You Stop
The compounded GLP-1 market closes June 29, 2026. STEP 1 trial data shows ~2/3 of lost weight returns after stopping. Here's how to build a tracking system before access changes.
BPC-157's First Randomized Human Clinical Trial: What NCT07437547 Actually Tells Us
A Phase 2 randomized controlled trial of BPC-157 for hamstring muscle strain has been registered on ClinicalTrials.gov. Here's what that means — and what it doesn't.
The GLP-1 Rebound Problem: What the Clinical Data Actually Shows — and What to Do About It
Two-thirds of weight lost on semaglutide returns within 12 months of stopping. The STEP 1 and SURMOUNT-4 trial data explains why — and what the research says actually helps.
TRIUMPH-1: Why the Most Interesting Number in Retatrutide's Phase 3 Trial Isn't 28%
Eli Lilly's TRIUMPH-1 Phase 3 trial showed 28% weight loss at 12mg retatrutide. But the real story is in the 4mg column — and it changes how most patients should think about this drug.
Women, GLP-1s, and Lean Mass: What the Research Actually Shows About Muscle Preservation During Fat Loss
GLP-1 medications cause both fat and muscle loss in women. Here's what the research says about preserving lean mass during fat loss — and why it matters more than the number on the scale.
How Long Can You Stay On Peptides? The Three-Bucket Framework
Most peptide cycle length advice is wrong because it ignores mechanism. Here's the three-bucket framework that tells you when to run forever, when to stop, and when to cycle hard.
BPC-157, TB-500, and Epithalon: What's Actually Happening with FDA Reclassification in 2026
BPC-157 and TB-500 left the FDA's Category 2 restricted list on April 23, 2026. The FDA's PCAC meets July 23–24 to formally review 7 peptides for 503A approval. Here's what actually happened.
Forzinity (SS-31) Receives FDA Accelerated Approval — Here's What It Means for the Peptide Field
SS-31 (Forzinity) received FDA accelerated approval in September 2025 for mitochondrial dysfunction — the first peptide of its class to cross from gray market to approved drug.